Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue.
Publication
, Conference
Chintagumpala, M; Ashley, D; Hassall, T; Wallace, D; Merchant, TE; Woo, S; Sexton, M; Cheuk, R; Gajjar, A
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 1, 2005
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2005
Volume
23
Issue
16
Start / End Page
813S / 813S
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
41st Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Chintagumpala, M., Ashley, D., Hassall, T., Wallace, D., Merchant, T. E., Woo, S., … Gajjar, A. (2005). Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 23, pp. 813S-813S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
Chintagumpala, M., D. Ashley, T. Hassall, D. Wallace, T. E. Merchant, S. Woo, M. Sexton, R. Cheuk, and A. Gajjar. “Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue.” In JOURNAL OF CLINICAL ONCOLOGY, 23:813S-813S. AMER SOC CLINICAL ONCOLOGY, 2005.
Chintagumpala M, Ashley D, Hassall T, Wallace D, Merchant TE, Woo S, et al. Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2005. p. 813S-813S.
Chintagumpala, M., et al. “Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue.” JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 16, AMER SOC CLINICAL ONCOLOGY, 2005, pp. 813S-813S.
Chintagumpala M, Ashley D, Hassall T, Wallace D, Merchant TE, Woo S, Sexton M, Cheuk R, Gajjar A. Excellent event-free survival (EFS) in newly diagnosed patients with supratentorial primitive neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and stem cell rescue. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2005. p. 813S-813S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 1, 2005
Volume
23
Issue
16
Start / End Page
813S / 813S
Location
Orlando, FL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
41st Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences